The effect of transcranial magnetic stimulation combined with sertraline on post-stroke depression
10.3760/cma.j.cn115455-20201126-01687
- VernacularTitle:经颅磁刺激联合舍曲林对卒中后抑郁的临床疗效
- Author:
Yonggang ZHANG
1
;
Pei WANG
;
Chuanpeng WANG
Author Information
1. 淄博市第五人民医院精神科，淄博 255100
- Keywords:
Depression;
Stroke;
Transcranial magnetic stimulation;
Sertraline;
Treatment outcome
- From:
Chinese Journal of Postgraduates of Medicine
2022;45(6):498-501
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of transcranial magnetic stimulation (TMS) combined with sertraline on post-stroke depression (PSD).Methods:A total of 94 PSD patients admitted Zibo Fifth People's Hospital from June 2018 to June 2020 were selected as the research objects, and they were divided into observation group (47 cases) and control group (47 cases) according the treatment methods. The control group was treated with TMS, and the observation group was treated with TMS combined with sertraline. After treatment of 12 weeks, the clinical effects, neurological function scores, serological indicators, cognitive function and incidence of adverse reactions of the two groups were evaluated and compared.Results:The total effective rate in the observation group was higher than that in the control group: 91.49% (43/47) vs. 72.34% (34/47), the difference was statistically significant (χ 2 = 5.82, P<0.05). After treatment, the scores of National Institutes of Health Stroke Scale(NIHSS) and Hamilton′s Depression Scale -17 (HAMD-17) in the observation group were lower than those in the control group: (5.45 ± 1.97) scores vs. (7.89 ± 2.18) scores, (8.18 ± 2.34) scores vs. (10.27 ± 2.97) scores; the scores of Glasgow Coma Scale (GCS) in the observation group were higher than those in the control group: (26.23 ± 3.18) scores vs. (23.42 ± 2.90) scores, the differences were statistically significant ( P<0.01). After treatment, the level of C-reactive protein (CRP) in the observation group was lower than that in the control group: (8.28 ± 2.78) mg/L vs. (10.76 ± 2.99) mg/L; the level of 5-hydroxytryptamine (5-HT) in the observation group was higher than that in the control group: (196.12 ± 20.71) μmol/L vs. (177.98 ± 19.94) μmol/L, the differences were statistically significant ( P<0.01). After treatment, the scores of cognitive function screening scale (CASI) in the observation group, including attention, orientation, memory, fluency of thinking and language expression were higher than those in the control group ( P<0.05). The incidence of adverse reactions in the two groups had no significant difference ( P>0.05). Conclusions:TMS combined with sertraline has a good effect on PSD, which can improve neurological function, serological indicators and cognitive function, with low adverse reactions.
